Skip to contentClarengateINTELLIGENCE
Companies/12217886

Immutrin Ltd

Research and experimental development on biotechnology · Cambridge

ActiveUnited KingdomIncorporated 2019Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

Accounts to 2025-08-31

IXBRL · 159 source facts · 24 selected values

Validation findings
XBRL valid
Reporting period
2024-09-01 to 2025-08-31
Extraction status
complete
Numeric facts
112
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2025-01-01.xsd
Currency
GBP
Source identifier
Prod224_2511_12217886_20250831
Source archive
Accounts_Monthly_Data-November2025.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2024-08-31

IXBRL · 131 source facts · 10 selected values

Validation findings
XBRL valid
Reporting period
2023-09-01 to 2024-08-31
Extraction status
complete
Numeric facts
87
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2022-01-01.xsd
Currency
GBP
Source identifier
Prod224_3500_12217886_20240831
Source archive
Accounts_Monthly_Data-January2025.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2023-08-31

IXBRL · 145 source facts · 12 selected values

Not assessed
legacy record
Reporting period
2022-09-01 to 2023-08-31
Extraction status
Legacy / not assessed
Numeric facts
96
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2022-01-01.xsd
Currency
GBP
Source identifier
Prod224_1966_12217886_20230831
Source archive
Accounts_Monthly_Data-April2024.zip

Accounts to 2022-08-31

IXBRL · 89 source facts · 18 selected values

Not assessed
legacy record
Reporting period
2021-09-01 to 2022-08-31
Extraction status
Legacy / not assessed
Numeric facts
42
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2021-01-01.xsd
Currency
GBP
Source identifier
Prod224_0112_12217886_20220831
Source archive
Accounts_Monthly_Data-November2022.zip

Accounts to 2021-08-31

IXBRL · 90 source facts · 18 selected values

Not assessed
legacy record
Reporting period
2020-09-01 to 2021-08-31
Extraction status
Legacy / not assessed
Numeric facts
44
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2021-01-01.xsd
Currency
GBP
Source identifier
Prod224_0102_12217886_20210831
Source archive
Accounts_Monthly_Data-February2022.zip

Accounts to 2020-08-31

IXBRL · 71 source facts · 9 selected values

Not assessed
legacy record
Reporting period
2019-09-20 to 2020-08-31
Extraction status
Legacy / not assessed
Numeric facts
23
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2019-01-01.xsd
Currency
GBP
Source identifier
Prod224_0088_12217886_20200831
Source archive
Accounts_Monthly_Data-March2021.zip

Registered details

12217886
Status
Active
Type
Private Limited Company
Incorporated
2019-09-20
Jurisdiction
—
Registered office
CAMBRIDGE INNOVATION CAPITAL, 22 STATION ROAD, CAMBRIDGE, CB1 2JD, UNITED KINGDOM

Classification

1 SIC codes
72110

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

3 SH01-derived rounds
2026-04-17
£19,464,144 raised
£34,575,504 estimated post-money
Venture
2026-02-10
£3,749,952 raised
£15,111,360 estimated post-money
Venture
2023-04-04
£949,964 raised
£5,540,879 estimated post-money
Venture

Research and innovation

1 matched grants
Antibody Immunotherapy for Systemic and Local AmyloidosisLead
Innovate UK · Collaborative R&D · 2023-02-01 – 2024-07-31
£700,000
awarded